Iovance Biotherapeutics, INC

Iovance Biotherapeutics updated its corporate presentation, showcasing advancements in its Tumor Infiltrating Lymphocyte (TIL) therapies, including strong clinical data for Amtagvi and a promising pipeline for various solid tumors.

Iovance Biotherapeutics announced record second-quarter 2026 revenue of $99.3 million, a 66% year-over-year increase, alongside significant clinical and regulatory advancements for its TIL therapies.

Iovance Biotherapeutics received marketing authorization from the Australian Therapeutic Goods Administration for its T cell therapy, Amtagvi, to treat advanced melanoma.

Iovance Biotherapeutics announced robust first quarter 2026 financial results, showcasing significant year-over-year revenue growth and providing optimistic guidance for the remainder of the year.

Iovance Biotherapeutics announced that Board member Wendy Yarno will retire and not seek re-election at the upcoming annual meeting.

Iovance Biotherapeutics announced robust fourth quarter and full year 2025 financial results, driven by Amtagvi demand and significant pipeline advancements.

Iovance Biotherapeutics announced a significant increase in revenue for the quarter ended June 30, 2026, driven by strong sales of Amtagvi and Proleukin, though net losses persist.

Iovance Biotherapeutics Inc. reported a 45% increase in total revenue for the first quarter of 2026, driven by strong Amtagvi and Proleukin sales, while net loss narrowed.

Iovance Biotherapeutics reported strong 37% growth in Amtagvi revenue for Q3 2025, alongside a strategic restructuring, increased net losses, and the withdrawal of its European marketing application for lifileucel.

Iovance Biotherapeutics reported increased net losses in Q2 2025 despite significant Amtagvi revenue growth, alongside a strategic workforce reduction and ongoing legal challenges.

Iovance Biotherapeutics announced its first quarter 2025 financial results, highlighting initial revenue from its newly launched advanced melanoma drug Amtagvi and ongoing Proleukin sales, alongside progress in its clinical pipeline and international regulatory filings.

Iovance Biotherapeutics reports a significant increase in revenue for Q3 2024, primarily driven by the commercial launch of Amtagvi and sales of Proleukin.

Iovance Biotherapeutics reports increased Amtagvi revenue and ongoing clinical trials, alongside a net loss of $391.0 million for fiscal year 2025.

Iovance Biotherapeutics reports its 2024 financial results, highlighting the commercial launch of Amtagvi and continued advancement of its TIL therapy pipeline.

Iovance Biotherapeutics' 10-K filing highlights the FDA approval and commercial launch of Amtagvi, along with progress in its TIL therapy pipeline and manufacturing capabilities.

Daniel Gordon Kirby, Chief Commercial Officer of Iovance Biotherapeutics, Inc., reported multiple transactions in common stock on August 10, 2026.

Corleen M. Roche, Chief Financial Officer of Iovance Biotherapeutics, Inc., reported multiple transactions in common stock on August 6, 2026.

IOVA Director Michael Weiser reported the grant of 90,316 Deferred Restricted Stock Units (DRSUs) on June 16, 2026, with vesting contingent on continued service and issuance deferred until specific events.

Iain Dukes, a Director at IOVANCE BIOTHERAPEUTICS, INC., acquired 180,632 Deferred Restricted Stock Units on June 16, 2026.

IOVA Director Athena Countouriotis has reported the grant of 90,316 Deferred Restricted Stock Units (DRSUs) under the company's equity incentive plan.

IOVANCE BIOTHERAPEUTICS, INC. Director Ryan Maynard was granted 90,316 Deferred Restricted Stock Units (DRSUs) on June 16, 2026, with vesting and issuance subject to service and specific future events.

Iovance Biotherapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on June 10, 2026, featuring proposals for director elections, executive compensation, and an increase in authorized common stock.

Iovance Biotherapeutics announces its 2025 Annual Meeting of Stockholders, urging investors to vote on key proposals including director elections, executive compensation, auditor ratification, and equity incentive plan amendments.

Iovance Biotherapeutics announces its 2025 Annual Meeting of Stockholders to be held virtually on June 10, 2025, including proposals for director elections and amendments to equity incentive plans.

Iovance Biotherapeutics issues a supplement to its proxy statement to clarify voting standards and the treatment of abstentions and broker non-votes for Proposals 4 and 5 at the upcoming annual meeting.

Iovance Biotherapeutics is holding its annual shareholder meeting on June 11, 2024, to vote on the election of directors, executive compensation, ratification of the accounting firm, and amendments to equity incentive plans.

Iovance Biotherapeutics is asking stockholders to approve amendments to its 2018 Equity Incentive Plan and 2020 Employee Stock Purchase Plan at the upcoming annual meeting on June 11, 2024.

State Street Corporation has reported a beneficial ownership of 5.5% in Iovance Biotherapeutics Inc. through a Schedule 13G filing.

State Street Corporation has reported a beneficial ownership of 4.2% in Iovance Biotherapeutics Inc. as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting a 0% beneficial ownership stake in Iovance Biotherapeutics Inc. following an internal corporate realignment.

State Street Corporation has reported a 5.1% beneficial ownership stake in Iovance Biotherapeutics Inc., holding over 20 million common shares as of December 31, 2025.

The Vanguard Group has filed an amended Schedule 13G, disclosing a 7.50% beneficial ownership stake in Iovance Biotherapeutics Inc., totaling 25,076,472 common shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.4% beneficial ownership stake in Iovance Biotherapeutics, Inc. as of June 30, 2025.